Cargando…

The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer

BACKGROUND: The waiting interval after chemoradiotherapy (CRT) is an interesting therapeutic window to treat patients with synchronous liver metastases (SLM) from rectal cancer. METHODS: A retrospective analysis was performed of 18 consecutive patients (M/F 10/8, age (range) 60 (51–75) years) from f...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Hondt, Mathieu, Lucidi, Valerio, Vermeiren, Koen, Van Den Bossche, Bert, Donckier, Vincent, Sergeant, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335842/
https://www.ncbi.nlm.nih.gov/pubmed/28253875
http://dx.doi.org/10.1186/s12957-017-1123-6
_version_ 1782512115330842624
author D’Hondt, Mathieu
Lucidi, Valerio
Vermeiren, Koen
Van Den Bossche, Bert
Donckier, Vincent
Sergeant, Gregory
author_facet D’Hondt, Mathieu
Lucidi, Valerio
Vermeiren, Koen
Van Den Bossche, Bert
Donckier, Vincent
Sergeant, Gregory
author_sort D’Hondt, Mathieu
collection PubMed
description BACKGROUND: The waiting interval after chemoradiotherapy (CRT) is an interesting therapeutic window to treat patients with synchronous liver metastases (SLM) from rectal cancer. METHODS: A retrospective analysis was performed of 18 consecutive patients (M/F 10/8, age (range) 60 (51–75) years) from five institutions who underwent liver resection of SLM during the waiting interval after CRT for rectal adenocarcinoma. RESULTS: All patients underwent interval liver surgery for a median (range) of 4 (2–14) liver metastases. Metastases involved a median (range) of 4 (1–7) liver segments. Median (range) time between end of CRT and liver surgery was 22 (6–45) days. Laparoscopic liver surgery was performed in 12 (67%) patients. No severe complications (Clavien-Dindo ≥ 3b) occurred after liver surgery. Median (range) length of hospital stay after liver surgery was 5 (1–10) days. All patients subsequently underwent rectal resection at a median (range) of 10 (8–13) weeks after end of CRT. Median (IQR) time-to-progression after liver surgery was 4.2 (2.8–9.2) months. CONCLUSIONS: The waiting interval after neoadjuvant CRT is a valuable option to treat SLM from rectal cancer. More data are necessary to confirm its oncological efficacy.
format Online
Article
Text
id pubmed-5335842
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53358422017-03-07 The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer D’Hondt, Mathieu Lucidi, Valerio Vermeiren, Koen Van Den Bossche, Bert Donckier, Vincent Sergeant, Gregory World J Surg Oncol Research BACKGROUND: The waiting interval after chemoradiotherapy (CRT) is an interesting therapeutic window to treat patients with synchronous liver metastases (SLM) from rectal cancer. METHODS: A retrospective analysis was performed of 18 consecutive patients (M/F 10/8, age (range) 60 (51–75) years) from five institutions who underwent liver resection of SLM during the waiting interval after CRT for rectal adenocarcinoma. RESULTS: All patients underwent interval liver surgery for a median (range) of 4 (2–14) liver metastases. Metastases involved a median (range) of 4 (1–7) liver segments. Median (range) time between end of CRT and liver surgery was 22 (6–45) days. Laparoscopic liver surgery was performed in 12 (67%) patients. No severe complications (Clavien-Dindo ≥ 3b) occurred after liver surgery. Median (range) length of hospital stay after liver surgery was 5 (1–10) days. All patients subsequently underwent rectal resection at a median (range) of 10 (8–13) weeks after end of CRT. Median (IQR) time-to-progression after liver surgery was 4.2 (2.8–9.2) months. CONCLUSIONS: The waiting interval after neoadjuvant CRT is a valuable option to treat SLM from rectal cancer. More data are necessary to confirm its oncological efficacy. BioMed Central 2017-03-02 /pmc/articles/PMC5335842/ /pubmed/28253875 http://dx.doi.org/10.1186/s12957-017-1123-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
D’Hondt, Mathieu
Lucidi, Valerio
Vermeiren, Koen
Van Den Bossche, Bert
Donckier, Vincent
Sergeant, Gregory
The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
title The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
title_full The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
title_fullStr The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
title_full_unstemmed The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
title_short The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
title_sort interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335842/
https://www.ncbi.nlm.nih.gov/pubmed/28253875
http://dx.doi.org/10.1186/s12957-017-1123-6
work_keys_str_mv AT dhondtmathieu theintervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT lucidivalerio theintervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT vermeirenkoen theintervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT vandenbosschebert theintervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT donckiervincent theintervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT sergeantgregory theintervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT dhondtmathieu intervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT lucidivalerio intervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT vermeirenkoen intervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT vandenbosschebert intervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT donckiervincent intervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer
AT sergeantgregory intervalapproachanadaptationoftheliverfirstapproachtotreatsynchronouslivermetastasesfromrectalcancer